Impact of HCV Eradication on Neurocognitive Functions and CNS Metabolism: a Trial of Daclatasvir, Asunaprevir and BMS-791325 for Patients With HCV Genotype 1 Infection
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms HEPCOG-II
- 02 Jun 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 29 Apr 2015 Planned End Date changed from 1 Feb 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.
- 29 Apr 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.